1.
Lymphoma 2000.
The first international symposium on biology and treatment of aggressive lymphomas.
The stagnation seems to be over.
Ann Hematol 2001; 80 (Suppl 3): B1-B2.
2.
Coiffier B.: How to interpret the radiological abnormalities that persist after treatmentin non-Hodgkin`s lymphoma patients? Ann.
Oncol.
1999; 10 (10): 1141 (editorial).
3.
Coiffier B.,
Gisselbrecht C.,
Vose J.M.,
Tilly H.,
Herbrecht R.,
Bosly A.
et al: Prognostic factors in aggressive malignant lymphomas: Description and validation of prognostic index that could identify patients requiring a more intensive therapy.
J.
Clin.
Oncol.
1991; 9 (2): 211-9.
4.
Rankin S.C.
Assessment of response to therapy using conventional imaging.
Eur.
J.
Nucl.
Med.
Mol.
Imaging.
2003; 30 (1): 56-64.
5.
Hill M.,
Cunningham D.,
MacVicar D.,
Roldan A.,
Husband J.,
McCready R.
et al: Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.
J.
Clin.
Oncol.
1993; 11(11): 2273-8.
6.
Even-Sapir E.,
Israel O.
Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma.
Eur.
J.
Nucl.
Med.
Mol.
Imaging.
2003; 30 (1): 65-81.
7.
Friedberg J.W.,
Fischman A.,
Neuberg D.,
Kim H.,
Takvorian T.,
Andrea K.
NG.
et al.
FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.
Leuk.
Lymphoma.
2004; 45 (1): 85-92.
8.
Wirth A.,
Seymour J.F.,
Hicks R.J.,
Ware R.,
Fisher R.,
Prince M.
et al.
Fluorine-18 fluorodeoxyglucose positron emission tomography,
gallium-67 scintigraphy,
and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma.
Am.
J.
Med.
2002 (4); 112: 262-8.
9.
Tsukamoto N.,
Kojima M.,
Hasegawa M.,
Oriuchi N.,
Matsushima T.,
Yokohama A.
et al.
The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
Cancer.
2007; 110 (3): 652-9.
10.
Kostakoglu L.,
Leonard J.P.,
Kuji I.,
Coleman M.,
Vallabhajosula Sh.,
Stanley J.G.
Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Cancer.
2002; 94 (4): 879–88.
11.
Spaepen K.,
Stroobants S.,
Dupont P.
et al.
Prognostic value of positron emission tomography with fluorine-18 fluorodeoxyglucose after first line chemotherapy in non-Hodgkin`s lymphoma: is [18F]FDG-PET a valid alternative to convention diagnostic methods? J Clin Oncol 2001; 19: 414-419.